Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management

E Sechi, L Cacciaguerra, JJ Chen, S Mariotto… - Frontiers in …, 2022 - frontiersin.org
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges

A Al-Ani, JJ Chen, F Costello - Journal of Neurology, 2023 - Springer
New diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease
(MOGAD) have recently been proposed, distinguishing this syndrome from other …

Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide

JY Hor, K Fujihara - Frontiers in Neurology, 2023 - frontiersin.org
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an
inflammatory demyelinating disease of the central nervous system (CNS) with the presence …

Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management

W Ambrosius, S Michalak, W Kozubski… - International journal of …, 2020 - mdpi.com
Myelin oligodendrocyte glycoprotein (MOG)-associated disease (MOGAD) is a rare,
antibody-mediated inflammatory demyelinating disorder of the central nervous system …

Clinical characteristics and treatment of MOG-IgG–associated optic neuritis

DA Tajfirouz, MT Bhatti, JJ Chen - Current neurology and neuroscience …, 2019 - Springer
Abstract Purpose of Review Antibodies against myelin oligodendrocyte glycoprotein (MOG)
are associated with a unique acquired central nervous system demyelinating disease …

Treatment of MOG antibody associated disorders: results of an international survey

DH Whittam, V Karthikeayan, E Gibbons, R Kneen… - Journal of …, 2020 - Springer
Introduction While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein
antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus …

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations

M Juryńczyk, A Jacob, K Fujihara, J Palace - Practical neurology, 2019 - pn.bmj.com
The field of central nervous system (CNS) inflammatory diseases has recently broadened to
include a new condition associated with pathogenic serum antibodies against myelin …

Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

B Banwell, JL Bennett, R Marignier, HJ Kim… - The Lancet …, 2023 - thelancet.com
Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in
patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis …

Neurological update: MOG antibody disease

R Wynford-Thomas, A Jacob, V Tomassini - Journal of neurology, 2019 - Springer
Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is now recognised
as a nosological entity with specific clinical and paraclinical features to aid early diagnosis …

Myelin-oligodendrocyte glycoprotein antibody-associated disease

R Marignier, Y Hacohen, A Cobo-Calvo… - The Lancet …, 2021 - thelancet.com
Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently
identified autoimmune disorder that presents in both adults and children as CNS …